The invention is directed to novel indole carboxamide derivatives. Specifically, the invention is directed to compounds according to formula (I).
The compounds of the invention are inhibitors of IKK2 and can be useful in the treatment of disorders associated with inappropriate IKK2 (also known as IKKβ) activity, such as rheumatoid arthritis, asthma, and COPD (chronic obstructive pulmonary disease). Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting IKK2 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention
[EN] CHEMICAL COMPOUNDS<br/>[FR] COMPOSES CHIMIQUES
申请人:SMITHKLINE BEECHAM CORP
公开号:WO2007076286A2
公开(公告)日:2007-07-05
[EN] The invention is directed to novel indole carboxamide derivatives. Specifically, the invention is directed to compounds according to formula (I). The compounds of the invention are inhibitors of IKK2 and can be useful in the treatment of disorders associated with inappropriate IKK2 (also known as IKKß) activity, such as rheumatoid arthritis, asthma, and COPD (chronic obstructive pulmonary disease). Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting IKK2 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention. [FR] La présente invention concerne des dérivés d'indole carboxamide atypiques. L'invention est particulièrement dirigée vers les composés de formule (I). Les composés de cette invention sont des inhibiteurs de IKK3 et peuvent s'utiliser dans le traitement de troubles associés à une activité inadéquate d'IKK2 (aussi connue sous le nom d'IKKß), telle que l'arthrite rhumatoïde, l'asthme et la BPCO (bronchopneumopathie chronique obstructive). En conséquence, l'invention est destinée à des compositions pharmaceutiques comprenant un composé de l'invention. Cette invention est en outre dirigée vers des procédés d'inhibition de l'activité IKK2 et du traitement de troubles associés en utilisant un composé de l'invention ou une composition pharmaceutique comprenant un composé de l'invention